Benzodiazepines have been in use for over half a century. While they remain highly
prescribed, their unfavorable side-effect profile and abuse liability motivated a search for …

Schizophrenia is a debilitating illness with a lifetime prevalence estimate of 0.6% and
consists of symptoms from the positive, negative, and cognitive domains. Social support …

Background Anxiety disorders are the most common type of mental illness in Europe, with a
12-month prevalence of 14% among persons aged 14 to 65. Their onset is usually in …

Importance Although overall rates of opioid use have been plateauing, coprescriptions of
benzodiazepines and opioids have increased greatly in recent years. It is unknown whether …

We now recognise that withdrawal symptoms from antidepressants are common, and can be
severe and long-lasting in some people. Many withdrawal symptoms overlap with symptoms …

The first hypnotic barbiturate, barbital, was introduced into clinical practice in 1903, followed
by phenobarbital in 1912. 1 In subsequent years, multiple barbiturates were synthesized …

As tranquilizers, benzodiazepines have a wide range of clinical uses. Recently, there has
been a significant rise in the number of novel psychoactive substances, including designer …

Background: In Canada, low awareness of evidence-based interventions for the clinical
management of alcohol use disorder exists among health care providers and people who …

Previous research has demonstrated not only the feasibility of providing addiction treatment
to individuals in an acute care setting but also its efficacy. A recent metaanalysis …

Background: Benzodiazepines (BZDs) are among the most prescribed sedative hypnotics
and among the most misused and abused medications by patients, in parallel with opioids. It …